Halo Labs, founded in Philadelphia, Pennsylvania, is dedicated to revolutionizing biopharmaceutical drug product quality. The company's core mission is to enhance drug stability and safety through innovative particle analysis tools. Halo Labs offers the Aura family of particle analyzers, which utilize low volume, high throughput methods to identify and count visible and subvisible particles. These tools are designed to accelerate biotherapeutic development from pre-IND stages through clinical phases and into manufacturing, focusing on improving decision-making for candidate selection, formulation, and quality control.

Notable figures affiliated with Halo Labs include industry experts in biopharmaceutical development and particle analysis technology. The company has garnered significant attention from investors interested in cutting-edge biopharma solutions. Key achievements include the successful commercialization of their particle analyzers, which have been adopted by leading biopharmaceutical companies to streamline their development processes. Halo Labs' impact lies in its ability to provide powerful, data-driven insights that enhance drug safety and efficacy, ultimately contributing to the advancement of global healthcare.